Avicanna Announces Date of Upcoming Annual General and Special Meeting of Shareholders
Avicanna Inc. ("Avicanna
" or the
”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a
biopharmaceutical company focused on the development, manufacturing
and commercialization of plant-derived cannabinoid-based products
is pleased to announce that its annual general and special meeting
of shareholders will be held virtually on August 31, 2022 at 10:30
AM (Toronto Time) (the “Meeting
Materials for the meeting (the “Meeting
Materials”) will be mailed to shareholders, and made
available under the Company’s profile on SEDAR at www.sedar.com and
on its website at https://ir.avicanna.com/, on or about August 10,
2022. The Meeting Materials will provide, among other things, a
description of the matters to be considered at the Meeting and
information as to how to access and participate in the Meeting.
The Company announces the following relevant
dates in respect of its upcoming Shareholders’ Meeting:
Record Date: July 27, 2022Proxy Cut-Off: August 29, 2022 at
10:30 AM (Toronto Time)Meeting Date: August 31, 2022 at 10:30 AM
The Toronto Stock Exchange has granted the
Company an extension to hold its annual shareholder meeting this
year on or before August 31, 2022.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
Medical Cannabis & Wellness
Products: Marketed under the RHO Phyto™ brand these
medical and wellness products are a line of pharmaceutical-grade
cannabinoid products containing varying ratios of cannabidiol
(“CBD”) and tetrahydrocannabinol
(“THC”). The product portfolio contains a full
formulary of products including oral, sublingual, topical, and
transdermal deliveries that have controlled dosing, enhanced
absorption and stability studies supported by pre-clinical data.
The formulary is marketed with consumer, patient and
medical-community education and training.
Leveraging Avicanna’s scientific platform, vertical integration,
and real-world evidence, Avicanna has created a pipeline of
patent-pending drug candidates that are indication-specific and in
various stages of clinical development and commercialization. These
cannabinoid-based drug candidates look to address unmet medical
needs in the areas of dermatology, chronic pain, and various
neurological disorders. Avicanna’s first pharmaceutical preparation
(Trunerox™) is in the drug registration stage in South America.
Click to watch Avicanna’s Corporate Video
SOURCE Avicanna Inc.
For more information about Avicanna, visit
www.avicanna.com, contact Ivana Maric by email at email@example.com
or follow us on social media on LinkedIn , Twitter , Facebook or
The Company posts updates through videos from
the official Company YouTube channel.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified using words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions. Forward-looking information contained in this news
release includes, without limitation, statements related to the
timing of the Meeting and the delivery of the Meeting Materials.
Although the Company believes that the expectations and assumptions
on which such forward looking information is based are reasonable,
undue reliance should not be placed on the forward-looking
information because the Company can give no assurance that they
will prove to be correct. Actual results and developments may
differ materially from those contemplated by these statements.
Forward-looking information is subject to a variety of risks and
uncertainties that could cause actual events or results to differ
materially from those projected in the forward-looking information.
Such risks and uncertainties include but are not limited to current
and future market conditions, including the market price of the
common shares of the Company, and the risk factors set out in the
Company’s annual information form dated March 31, 2022 filed with
the Canadian securities regulators and available under the
Company’s profile on SEDAR at www.sedar.com. The statements in this
news release are made as of the date of this release. The Company
disclaims any intent or obligation to update any forward-looking
information, whether as a result of new information, future events
or results or otherwise, other than as required by applicable
Gráfico Histórico do Ativo
De Dez 2022 até Jan 2023
Gráfico Histórico do Ativo
De Jan 2022 até Jan 2023